Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with ...

Ipsen has suffered a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended against approval.

With FDA approval, Ipsen's marathon effort to bring palovarotene to market for the rare disease fibrodysplasia ossificans progressiva (FOP) has finally crossed the finish line in the US ...

Ipsen is a growing biopharma company that combines a dynamic, biotech mindset with the resources that come from having 5,400 employees and a direct presence in more than 30 countries. This ...

New progress in a long-standing debate about the nature of biological cell membranes could be made by considering which ...

Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potential BMX-502 is a bispecific antibody ...

Laura Ipsen is president and CEO of Ellucian, the leading technology solutions provider for more than 2,900 higher education institutions in 50 countries. She has more than 25 years of experience ...

“We predict in 2025 the biggest disrupter to tech in general will be the adoption of AI agents,” wrote Adam Ipsen, lead content strategist at Pluralsight. The LangChain software framework can ...

On Tuesday, RBC Capital Markets updated its outlook for shares of Ipsen (EPA:IPN) SA, a biopharmaceutical company, by increasing the price target from EUR 140.00 to EUR 144.00 while maintaining an ...